SPRINGWORKS THERAPEUTICS, INC. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
SPRINGWORKS THERAPEUTICS, INC. reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$45.57 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-02-25.
Discontinued › Income Statement
us-gaap:ProfitLoss · last filed 2021-02-25
- SPRINGWORKS THERAPEUTICS, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2020-12-31 was $11.27M.
- SPRINGWORKS THERAPEUTICS, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2020-09-30 was -$21.66M.
- SPRINGWORKS THERAPEUTICS, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2020-06-30 was -$19.89M.
- SPRINGWORKS THERAPEUTICS, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2020-03-31 was -$15.29M.
- SPRINGWORKS THERAPEUTICS, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2020 was -$45.57M.
- SPRINGWORKS THERAPEUTICS, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2019 was -$58.31M.
- SPRINGWORKS THERAPEUTICS, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2018 was -$17.81M.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 4 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|---|
| 2020-12-31 | $11.27M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | -$10.39M derived: sum of 2 quarters · filed 2021-02-25 | -$30.28M derived: sum of 3 quarters · filed 2021-02-25 | -$45.57M 10-K · filed 2021-02-25 | |
| 2020-09-30 | -$21.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | -$41.55M derived: sum of 2 quarters · filed 2020-11-12 | -$56.85M 10-Q · filed 2020-11-12 | -$73.06M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2020-06-30 | -$19.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12 | -$35.19M 10-Q · filed 2020-08-12 | -$51.40M derived: sum of 3 quarters · filed 2021-02-25 | -$68.24M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2020-03-31 | -$15.29M 10-Q · filed 2020-05-12 | -$31.51M derived: sum of 2 quarters · filed 2021-02-25 | -$48.34M derived: sum of 3 quarters · filed 2021-02-25 | -$62.19M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2019-12-31 | -$16.22M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | -$33.05M derived: sum of 2 quarters · filed 2021-02-25 | -$46.90M derived: sum of 3 quarters · filed 2021-02-25 | -$58.31M 10-K · filed 2021-02-25 | |
| 2019-09-30 | -$16.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | -$30.68M derived: sum of 2 quarters · filed 2020-11-12 | -$42.09M 10-Q · filed 2020-11-12 | -$48.31M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2019-06-30 | -$13.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12 | -$25.26M 10-Q · filed 2020-08-12 | -$31.48M derived: sum of 3 quarters · filed 2021-02-25 | ||
| 2019-03-31 | -$11.41M 10-Q · filed 2020-05-12 | -$17.63M derived: sum of 2 quarters · filed 2021-02-25 | |||
| 2018-12-31 | -$6.22M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | -$17.81M 10-K · filed 2021-02-25 | |||
| 2018-09-30 | -$11.59M 10-Q · filed 2019-11-12 | ||||
| 2017-12-31 | -$4.64M 10-K · filed 2020-03-12 |